{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Survey Questionnaire

  1. Asian Indians have been found to develop cardiovascular diseases at young age than Caucasians *

  2. Asian Indians have a unique pattern of dyslipidemia characterized by *

  3. South Asians manifest CVD at lower levels of total cholesterol compared with other ethnic groups *

  4. Considering the higher CV mortality in our country, do you feel threshold for various cholesterol levels to initiate treatment should be lower than western counterparts *

  5. Do you believe that elevated LDL Cholesterol is an important cause of coronary cause of coronary artery disease and ischemic stroke? *

  6. How many Patients do you encounter with Dyslipidemia in your daily practice? *

  7. Right down the % of patients having following risk factors along with dyslipidemia in your daily practice? *

    8. %

    %

    %

    %

    %
  8. Which Method do you use to stratify cardiovascular risk in your patients? *

  9. What is your choice of Statin for Primary Prevention ? Please mention the use in % *

    10. %

    %

    %
  10. Do you prescribe statin to all diabetic patients above 50 years with multiple risk factors, but not CHD *

  11. Which statin do you prefer for diabetic patients? *

  12. What is your preferred drug option for patients with LDL >160 mg /dL, TG 200-499 mg /dL, and HDL < 40mg/dL without CHD or CHD risk equivalent? *
    (Give order of preference in case of multiple options)
    13. Molecule /Drug Preference

  13. What LDL-C targets or Goals do you prefer for your patients of primary prevention? *

  14. If LDL-C goal is achieved do you also keep the non-HDL-C target? *

  15. Do you alter existing therapy to attain non-HDL-C goal in patients with LDL levels at Goal *

  16. If yes, then which is your preferred strategy to attain non-HDL-C goal in these patients *

  17. The combination of high levels of Lp(a) and homocysteine, and high prevalence of diabetes, metabolic syndrome, and Asian Indian dyslipidaemia— and the synergistic interaction among these risk factors — best explains the high prevalence of premature, severe, diffuse, multi-vessel malignant CAD among Indians globally ( Do you agree / Disagree) *

  18. In approximately what % of your patients do you recommend hs-CRP testing? *

  19. What is your choice of statin for secondary prevention? *

  20. The Key components of Anti-thrombotic therapy for ACS patients include *

  21. In your opinion fixed dose combinations of statin and anti-platelet drugs have the following advantage *

  22. Fixed dose combinations of statin and anti-platelet drugs improve patient compliance and adherence *

  23. In your ACS Patients; for how long do you prefer Statin + DAPT Combination *

  24. In your opinion, is Rosuvastatin and Clopidogrel combination therapy beneficial for more effective management of Cardiovascular disease ? *

  25. Do you agree that early intensive Rosuvastatin use in ACS patients if effective in improving 12-month Outcomes? *

  26. Patients with postoperative myocardial infarction receiving dual anti-platelet therapy in combination with statin therapy has improved survival rates of *

  27. Triple drug therapy with dual anti-platelet therapy and lipid lowering statin helps in *

  28. Triple fixed dose combination therapy of Aspirin, Clopidogrel and Rosuvastatin was the most preferred choice of physicians, for optimal management Post ACS Patient in Indian Setting *

  29. In Your opinion, usage pattern of Fixed dose combination of Rosuvastatin 10 mg + Clopidogrel 75 mg + Aspirin 75 mg dose once daily for 1-3 years is recommended for ACS patients *

  30. Combination of Clopidogrel with statin has synergistic effects on the clinical outcomes of patients with ACS *

  31. Benefits of antiplatelet agents and statin before surgery include *

  32. Do you agree that antiplatelet and statin therapy in the perioperative period is associated with improved 30 day mortality and improved 5 year survival? *

  33. Dual antiplatelet therapy and high intensity statins are the mainstay treatments for intracranial atherosclerosis *

  34. In your opinion, does Rosuvastatin Plus Clopidogrel therapy effectively improve cardiac function parameter LVEF and Decrease wall motion score index in elderly CHD patients ? *

  35. Statin’s antithrombotic effects are additive to those exerted by standard dose of Clopidogrel *

  36. Pleotropic effects of Statin, apart from cholesterol lowering actions include *

  37. Statins play a key role in nephroprotection and myocardial protection after contrast medium administration of during PCI *

  38. Commonly prescribed dosage of triple drug therapy of Rosuvastatin and dual antiplatelet therapy is *

  39. Rosuvastatin has no effect on inhibition of platelet aggregation exerted by Aspirin or Clopidogrel *

  40. Which of the following Statins according to you has higher capacity of LDL Cholesterol lowering? *

  41. IN ACS management, high dose of Rosuvastatin is superior compared with high dose of Atorvastatin for lipid modification in ACS with similar safety and tolerability *

  42. Absence of combined antiplatelet and statin therapy at discharge after postoperative MI is associated with higher late mortality *

  43. High dose of Rosuvastatin administration early on admission results in a significantly lower incidence of Contrast Induced Acute Kidney Injury *

  44. Antiplatelets and statins are effective in preventing future cardiovascular events in patients with CHD *

  45. Disparity in cardiovascular outcomes exists by race /ethnicity and gender *

  46. Do you think that statins and antiplatelet combination therapy is underused? *

  47. Do you think high levels if initial prescription have not translated into long term treatment of CHD *

  48. Adherence to medication, Post MI is higher than ACS *

  49. A fixed dose combination of pill containing Aspirin, a Statin, and > 1 BP loweing agent could help to optimize the prevention of CV disease *

  50. DAPT along with Statin reduces the risk of CV events *

  51. The benefits of combined anti-platelet and Statin are greater than the simple arithmetic sum of the benefits of each agent *

  52. CHD and Stroke are the top two causes of death globally *

  53. National Institute for Health and Care excellence (NICE), European Society of Cardiology (ECS), American College of Cardiology / American Heart Association ( ACC/AHA ) & American Heart Association / American Stroke Association ( AHA / ASA ) recommend antiplatelet agents, and lipid lowering drugs for secondary prevention of CVD *

  54. Unless contraindicated, antiplatelet agents should be considered as the first component of evidence based combination pharmacotherapy (EBCP) in the secondary prevention of CHD *

  55. If a Patient has 1-year old history or previous MI, What Strategies would you follow *

  56. Which is your preferred statin post-ACS? (Please specify dose used for the statin selected) *

    57. mg

    mg
  57. When prescribing a statin, which of the following factors do you consider important while deciding the dose of statin *

  58. Do you agree that early, more aggressive lipid lowering regimen of statin high dose provides greater benefit against death or CV events in ACS patients? *

  59. If Statin dose is lowered Post Stroke or TIA (Deintensification) there are either high chances of increased mortality or no benefit v/s the patient who have been given statin dosing as per the goal *

  60. Please indicate the percentage of patients who can not use statins continuously due to adverse effects (Such as Muscle symptoms etc. ) (0 % I have no Statin - Intolerant patients ) *

  61. What is your preferred approach for patients presenting with statin intolerance *

  62. A patient has been taking rosuvastatin high dose and reports to you he /she is experiencing soreness and weakness of the muscle. What lab investigation will you suggest immediately? *

  63. Due to Statin non-compliance the LDL reduction can delay up to what time period according to you (Consider Compliance level of a patient as 50 %) *

  64. Do you think Statins have any effect on cognitive function ? *

  65. Please indicate the percentage of patients who can not use statins continuously due to adverse effects ( Such as muscle symptoms etc) *

  66. Please indicate your target level of LDL Cholesterol after initiation of drug therapy in the following patient groups *

    67. mg/dl

    mg/dl

    mg/dl
  67. Do you have concerns about safety if the LDL Cholesterol is below the following levels? *

  68. Do you think markedly low LDL Cholesterol levels affect the incidence of haemorrhagic stroke? *

  69. How much does the LDL cholesterol level affect the risk of inducing atherosclerotic cardiovascular diseases? *

  70. Do you sometimes use “non-HDL cholesterol level” as a risk index of atherosclerotic cardiovascular diseases (ASCVD, coronary artery diseases, non-cardiogenic cerebral infarction) or a therapeutic efficacy index during your medical practice? *

  71. Concerning Familial Hypercholesterolaemia (FH, one type of primary hyperlipidaemia), which best reflects your practice? *

  72. When you make a diagnosis of FH in an adult patient (15-year-old or older), do you perform the followings? (More than one item can be selected) *

  73. How do you treat CKD patients with hypertriglyceridemia? *